An investigation of the effects of lipid-lowering medications

Genome-wide linkage analysis of lipids in the HyperGEN study

Jun Wu, Michael A. Province, Hilary Coon, Steven Hunt, John H. Eckfeldt, Donna K. Arnett, Gerardo Heiss, Cora E. Lewis, R. Curtis Ellison, Dabeeru C. Rao, Treva Rice, Aldi T. Kraja

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Use of anti-hyperlipidemic medications compromises genetic analysis because of altered lipid profiles. We propose an empirical method to adjust lipid levels for medication effects so that the adjusted lipid values substitute the unmedicated lipid values in the genetic analysis. Results: Published clinical trials were reviewed for HMG-CoA reductase inhibitors and fibric acid derivatives as mono-drug therapy. HMG-CoA reductase inhibitors showed similar effects in African Americans (AA) and non-African Americans (non-AA) for lowering total cholesterol (TC, -50.7 mg/dl), LDL cholesterol (LDL-C, -48.1 mg/dl), and triglycerides (TG, -19.7 mg/dl). Their effect on increasing HDL cholesterol (HDL-C) in AA (+0.4 mg/dl) was lower than in Non-AA (+2.3 mg/dl). The effects of fibric acid derivatives were estimated as -46.1 mg/dl for TC, -40.1 mg/dl for LDL-C, and +5.9 mg/dl for HDL-C in non-AA. The corresponding effects in AA were less extreme (-20.1 mg/dl, -11.4 mg/dl, and +3.1 mg/dl). Similar effect for TG (59.0 mg/dl) was shown in AA and non-AA. The above estimated effects were applied to a multipoint variance components linkage analysis on the lipid levels in 2,403 Whites and 2,214 AA in the HyperGEN study. The familial effects did vary depending on whether the lipids were adjusted for medication use. For example, the heritabilities increased after medication adjustment for TC and LDL-C, but did not change significantly for HDL-C and TG. Conclusion: Ethnicity-specific medication adjustments using our empirical method can be employed in epidemiological and genetic analysis of lipids.

Original languageEnglish
Article number60
JournalBMC Genetics
Volume8
DOIs
Publication statusPublished - 10 Sep 2007
Externally publishedYes

Fingerprint

Genome
African Americans
Lipids
HDL Cholesterol
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Triglycerides
Cholesterol
Clinical Trials
Drug Therapy
oxidized low density lipoprotein

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

An investigation of the effects of lipid-lowering medications : Genome-wide linkage analysis of lipids in the HyperGEN study. / Wu, Jun; Province, Michael A.; Coon, Hilary; Hunt, Steven; Eckfeldt, John H.; Arnett, Donna K.; Heiss, Gerardo; Lewis, Cora E.; Ellison, R. Curtis; Rao, Dabeeru C.; Rice, Treva; Kraja, Aldi T.

In: BMC Genetics, Vol. 8, 60, 10.09.2007.

Research output: Contribution to journalArticle

Wu, J, Province, MA, Coon, H, Hunt, S, Eckfeldt, JH, Arnett, DK, Heiss, G, Lewis, CE, Ellison, RC, Rao, DC, Rice, T & Kraja, AT 2007, 'An investigation of the effects of lipid-lowering medications: Genome-wide linkage analysis of lipids in the HyperGEN study', BMC Genetics, vol. 8, 60. https://doi.org/10.1186/1471-2156-8-60
Wu, Jun ; Province, Michael A. ; Coon, Hilary ; Hunt, Steven ; Eckfeldt, John H. ; Arnett, Donna K. ; Heiss, Gerardo ; Lewis, Cora E. ; Ellison, R. Curtis ; Rao, Dabeeru C. ; Rice, Treva ; Kraja, Aldi T. / An investigation of the effects of lipid-lowering medications : Genome-wide linkage analysis of lipids in the HyperGEN study. In: BMC Genetics. 2007 ; Vol. 8.
@article{1c30475a5eb64755846a7416ca060bba,
title = "An investigation of the effects of lipid-lowering medications: Genome-wide linkage analysis of lipids in the HyperGEN study",
abstract = "Background: Use of anti-hyperlipidemic medications compromises genetic analysis because of altered lipid profiles. We propose an empirical method to adjust lipid levels for medication effects so that the adjusted lipid values substitute the unmedicated lipid values in the genetic analysis. Results: Published clinical trials were reviewed for HMG-CoA reductase inhibitors and fibric acid derivatives as mono-drug therapy. HMG-CoA reductase inhibitors showed similar effects in African Americans (AA) and non-African Americans (non-AA) for lowering total cholesterol (TC, -50.7 mg/dl), LDL cholesterol (LDL-C, -48.1 mg/dl), and triglycerides (TG, -19.7 mg/dl). Their effect on increasing HDL cholesterol (HDL-C) in AA (+0.4 mg/dl) was lower than in Non-AA (+2.3 mg/dl). The effects of fibric acid derivatives were estimated as -46.1 mg/dl for TC, -40.1 mg/dl for LDL-C, and +5.9 mg/dl for HDL-C in non-AA. The corresponding effects in AA were less extreme (-20.1 mg/dl, -11.4 mg/dl, and +3.1 mg/dl). Similar effect for TG (59.0 mg/dl) was shown in AA and non-AA. The above estimated effects were applied to a multipoint variance components linkage analysis on the lipid levels in 2,403 Whites and 2,214 AA in the HyperGEN study. The familial effects did vary depending on whether the lipids were adjusted for medication use. For example, the heritabilities increased after medication adjustment for TC and LDL-C, but did not change significantly for HDL-C and TG. Conclusion: Ethnicity-specific medication adjustments using our empirical method can be employed in epidemiological and genetic analysis of lipids.",
author = "Jun Wu and Province, {Michael A.} and Hilary Coon and Steven Hunt and Eckfeldt, {John H.} and Arnett, {Donna K.} and Gerardo Heiss and Lewis, {Cora E.} and Ellison, {R. Curtis} and Rao, {Dabeeru C.} and Treva Rice and Kraja, {Aldi T.}",
year = "2007",
month = "9",
day = "10",
doi = "10.1186/1471-2156-8-60",
language = "English",
volume = "8",
journal = "BMC Genetics",
issn = "1471-2156",
publisher = "BioMed Central",

}

TY - JOUR

T1 - An investigation of the effects of lipid-lowering medications

T2 - Genome-wide linkage analysis of lipids in the HyperGEN study

AU - Wu, Jun

AU - Province, Michael A.

AU - Coon, Hilary

AU - Hunt, Steven

AU - Eckfeldt, John H.

AU - Arnett, Donna K.

AU - Heiss, Gerardo

AU - Lewis, Cora E.

AU - Ellison, R. Curtis

AU - Rao, Dabeeru C.

AU - Rice, Treva

AU - Kraja, Aldi T.

PY - 2007/9/10

Y1 - 2007/9/10

N2 - Background: Use of anti-hyperlipidemic medications compromises genetic analysis because of altered lipid profiles. We propose an empirical method to adjust lipid levels for medication effects so that the adjusted lipid values substitute the unmedicated lipid values in the genetic analysis. Results: Published clinical trials were reviewed for HMG-CoA reductase inhibitors and fibric acid derivatives as mono-drug therapy. HMG-CoA reductase inhibitors showed similar effects in African Americans (AA) and non-African Americans (non-AA) for lowering total cholesterol (TC, -50.7 mg/dl), LDL cholesterol (LDL-C, -48.1 mg/dl), and triglycerides (TG, -19.7 mg/dl). Their effect on increasing HDL cholesterol (HDL-C) in AA (+0.4 mg/dl) was lower than in Non-AA (+2.3 mg/dl). The effects of fibric acid derivatives were estimated as -46.1 mg/dl for TC, -40.1 mg/dl for LDL-C, and +5.9 mg/dl for HDL-C in non-AA. The corresponding effects in AA were less extreme (-20.1 mg/dl, -11.4 mg/dl, and +3.1 mg/dl). Similar effect for TG (59.0 mg/dl) was shown in AA and non-AA. The above estimated effects were applied to a multipoint variance components linkage analysis on the lipid levels in 2,403 Whites and 2,214 AA in the HyperGEN study. The familial effects did vary depending on whether the lipids were adjusted for medication use. For example, the heritabilities increased after medication adjustment for TC and LDL-C, but did not change significantly for HDL-C and TG. Conclusion: Ethnicity-specific medication adjustments using our empirical method can be employed in epidemiological and genetic analysis of lipids.

AB - Background: Use of anti-hyperlipidemic medications compromises genetic analysis because of altered lipid profiles. We propose an empirical method to adjust lipid levels for medication effects so that the adjusted lipid values substitute the unmedicated lipid values in the genetic analysis. Results: Published clinical trials were reviewed for HMG-CoA reductase inhibitors and fibric acid derivatives as mono-drug therapy. HMG-CoA reductase inhibitors showed similar effects in African Americans (AA) and non-African Americans (non-AA) for lowering total cholesterol (TC, -50.7 mg/dl), LDL cholesterol (LDL-C, -48.1 mg/dl), and triglycerides (TG, -19.7 mg/dl). Their effect on increasing HDL cholesterol (HDL-C) in AA (+0.4 mg/dl) was lower than in Non-AA (+2.3 mg/dl). The effects of fibric acid derivatives were estimated as -46.1 mg/dl for TC, -40.1 mg/dl for LDL-C, and +5.9 mg/dl for HDL-C in non-AA. The corresponding effects in AA were less extreme (-20.1 mg/dl, -11.4 mg/dl, and +3.1 mg/dl). Similar effect for TG (59.0 mg/dl) was shown in AA and non-AA. The above estimated effects were applied to a multipoint variance components linkage analysis on the lipid levels in 2,403 Whites and 2,214 AA in the HyperGEN study. The familial effects did vary depending on whether the lipids were adjusted for medication use. For example, the heritabilities increased after medication adjustment for TC and LDL-C, but did not change significantly for HDL-C and TG. Conclusion: Ethnicity-specific medication adjustments using our empirical method can be employed in epidemiological and genetic analysis of lipids.

UR - http://www.scopus.com/inward/record.url?scp=35648987626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35648987626&partnerID=8YFLogxK

U2 - 10.1186/1471-2156-8-60

DO - 10.1186/1471-2156-8-60

M3 - Article

VL - 8

JO - BMC Genetics

JF - BMC Genetics

SN - 1471-2156

M1 - 60

ER -